This study shows that chronic CBD administration improves learning and memory and reduces anxiety in aged SAMP8 mice, with potential therapeutic implications for age-related cognitive decline.

PLoS ONE · Aug 14, 2025Peer-reviewedNeuroscience

Biochemical, biomarker, and behavioral characterization of the GrnR493X mouse model of frontotemporal dementia

Denise M. Smith, Geetika Aggarwal, Michael L. Niehoff, Spencer A. Jones, Subhashis Banerjee, Susan A. Farr, Andrew D. Nguyen

This study characterizes the GrnR493X mouse model of frontotemporal dementia, finding similar phenotypes to Grn knockout models but with differences in biomarker levels in heterozygous mice.

Molecular Neurobiology · May 2, 2024Peer-reviewedNeuroscience

Antisense oligonucleotides targeting the miR-29b binding site in the GRN mRNA increase progranulin translation

Geetika Aggarwal, Subhashis Banerjee, Spencer A. Jones, Yousri Benchaar, Jasmine Bélanger, Myriam Sévigny, Denise M. Smith, Michael L. Niehoff, Monica Pavlack, Ian Mitchelle S. de Vera, Terri L. Petkau, Blair R. Leavitt, Karen Ling, Paymaan Jafar‐Nejad, Frank Rigo, , Andrew D. Nguyen

This study shows that antisense oligonucleotides can increase progranulin protein levels by blocking miR-29b binding in GRN mRNA, offering a potential therapy for FTD.

Journal of Biological Chemistry · Nov 17, 2023Peer-reviewedNeuroscience

A dual MTOR/NAD+ acting gerotherapy

Jinmei Li, Sandeep Kumar, Kirill Miachin, Nicholas L. Bean, Ornella Halawi, Scott M. Lee, Jiwoong Park, Tanya Hans Pierre, Jin‐Hui Hor, Shi‐Yan Ng, K. Wallace, Niklas Rindtorff, Timothy M. Miller, Michael L. Niehoff, Susan A. Farr, , Timothy R. Peterson

This paper identifies BIOIO-1001 as a dual mTOR/NAD+ acting gerotherapy that reduces metabolic derangements, inflammation, and fibrosis in NASH and ALS models.

bioRxiv · Jan 16, 2023 · PreprintGenomics